Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging

Annals of Nuclear Medicine

Volumn 25, Issue 3, 2011, Pages 173-178

  Toriihara, Akira ^a   Yoshida, Katsuya ^b   Umehara, Isao ^b   Shibuya, Hitoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b ASAHI GENERAL HOSPITAL   (Japan)

Author keywords

Bowel; Dual time point; FDG; PET CT; Physiological uptake

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; ASCENDING COLON; ASYMPTOMATIC DISEASE; BOWEL UPTAKE SCORE; CECUM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DESCENDING COLON; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER EXAMINATION; MALE; NORMAL HUMAN; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOLOGIST; RECTUM; RETROSPECTIVE STUDY; SCORING SYSTEM; SIGMOID; SMALL INTESTINE; TRANSVERSE COLON; WHOLE BODY IMAGING;

AGED; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTESTINES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79959989508     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-010-0439-x     Document Type: Article

References (19)

1. Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol. 2005;33:145-55.
2. Shreve P, Bui CDH. Artifacts and normal variants in FDG PET. In: Wahl RL, editor. Principles and practice of PET and PET/CT. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2009. p.139-68.
3. Prabhakar HB, Sahani DV, Fischman AF, Mueller PR, Blake MA. Bowel hot spots at PET-CT. RadioGraphics. 2007;27:145-59.
4. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology. 2002;224:783-7. (Pubitemid 34919813)
5. Gutman F, Alberini JL, Wartski M, Vilain D, Le Stanc E, Sarandi F, et al. Incidental colonic focal lesions detected by FDG PET/ CT. Am J Roentgenol. 2005;185:495-500.
6. Otsuka H, Graham MM, Kubo A, Nishitani H. The effect of oral contrast on large bowel activity in FDG-PET/CT. Ann Nucl Med. 2005;19:101-8. (Pubitemid 40745692)
7. Blake MA, Setty BN, Cronin CG, Kalra M, Holalkere NS, Fischman AJ, et al. Evaluation of the effects of oral water and low-density barium sulphate suspension on bowel appearance on FDG-PET/CT. Eur Radiol. 2010;20:157-64.
8. Soyka JD, Strobel K, Veit-Haibach P, Schaefer NG, Schmid DT, Tschopp A, et al. Influence of bowel preparation before 18F-FDG PET/CT on physiologic 18F-FDG activity in the intestine. J Nucl Med. 2010;51:507-10.
9. Emmott J, Sanghera B, Chambers J, Wong WL. The effects of N-butylscopolamine on bowel uptake: an 18F-FDG PET study. Nucl Med Commun. 2008;29:11-6. (Pubitemid 351339335)
10. Murphy R, Doerger KM, Nathan MA, Lowe VJ. Pretreatment with diphenoxylate hydrochloride/atropine sulphate (lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis. Mol Imaging Biol. 2009;11:114-7.
11. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.
12. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-8. (Pubitemid 29467031)
13. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871-5. (Pubitemid 34747808)
14. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26:226-30. (Pubitemid 29139852)
15. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J Nucl Med. 2005;46:1819-24. (Pubitemid 46196643)
16. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547-54. (Pubitemid 32011597)
17. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22-30. (Pubitemid 29137735)
18. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-7. (Pubitemid 32852620)
19. Gontier E, Fourme E, Wartski M, Blondet C, Bonardel G, Le Stanc E, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95-9. (Pubitemid 350234148)